Adocia Valuation Multiples

Adocia Overview

About Adocia

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.

Founded

2005

HQ

Employees

104

Website

adocia.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $17M

EBITDA: ($2M)

EV

$110M

Valuation Multiples

Multiples.vc

Start free trial

Adocia Financials

Adocia reported last 12-month revenue of $17M and negative EBITDA of ($2M).

In the same LTM period, Adocia generated ($2M) in EBITDA losses and had net loss of ($3M).

Adocia P&L

In the most recent fiscal year, Adocia reported revenue of $11M and EBITDA of ($8M).

Adocia expects next 12-month revenue of XXX and NTM EBITDA of XXX

Adocia Stock Performance

Adocia has current market cap of $106M, and enterprise value of $110M.

Adocia's stock price is $5.44.

Adocia Valuation Multiples

Adocia trades at 6.6x EV/Revenue multiple, and (45.3x) EV/EBITDA.

Adocia Financial Valuation Multiples

As of April 18, 2026, Adocia has market cap of $106M and EV of $110M.

Equity research analysts estimate Adocia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Adocia has a P/E ratio of (32.7x).

Adocia Margins & Growth Rates

Adocia's revenue in the last 12 month grew by 143%.

Adocia's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Adocia's rule of 40 is 3018% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Adocia's rule of X is 7414% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Adocia Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Adocia M&A Activity

Adocia acquired XXX companies to date.

Last acquisition by Adocia was on XXXXXXXX, XXXXX. Adocia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Adocia Investment Activity

Adocia invested in XXX companies to date.

Adocia made its latest investment on XXXXXXXX, XXXXX. Adocia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).